drugset / Trial / NCT01003990
Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.
Timeline
- Start
- 2002-10
- Primary completion
- 2016-02
- Completion
- 2016-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | Oral |
| Subject | Atazanavir | Other / unclassified | 400 mg | Oral |
| Comparator | Lopinavir | Other / unclassified | 400 mg | Oral |
| Comparator | Tenofovir | Small molecule | 300 mg | Oral |
| Comparator | emtricitabine | Other / unclassified | 200 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |